Universal Health Services Inc. (UHS) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. UHS operates as a holding company with subsidiaries providing acute care hospital services and behavioral health care services across 39 U.S. states, Washington D.C., the United Kingdom, and Puerto Rico. As of March 31, 2025, the company owned or operated 362 inpatient facilities and 60 outpatient/other facilities.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Revenues | $4,099.7 million | $3,843.6 million |
| Income from Operations | $454.8 million | $388.8 million |
| Net Income Attributable to UHS | $316.7 million | $261.8 million |
| Diluted EPS | $4.80 | $3.82 |
| Operating Cash Flow | $360.0 million | $396.4 million |
| Total Debt (Carrying Value) | $4.6 billion | $4.5 billion |
| Cash & Equivalents | $126.8 million | $112.1 million |
| Effective Tax Rate | 23.5% | 20.9% |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by 6.7% ($256 million) year-over-year. This was driven by a 6.1% increase in "Same Facility" revenues and $27 million in new revenue from the West Henderson Hospital in Las Vegas, which opened in Q4 2024.
- Profitability: Net income attributable to UHS rose 21% ($55 million). Income before taxes increased 25% ($84 million), aided by a $13 million reduction in interest expense due to lower average borrowing costs (4.1% in Q1 2025 vs. 5.1% in Q1 2024) and lower outstanding borrowings.
- Segment Performance:
- Acute Care: Same facility revenues increased 6.5%. Income before taxes rose 31% to $270 million.
- Behavioral Health: Same facility revenues increased 5.5%. Income before taxes rose 7% to $341 million. UK behavioral health revenues were $227 million.
- Working Capital: Accounts receivable increased by $218 million, contributing to a $36 million decrease in operating cash flow. This was partly due to delays in receiving funds from certain Medicaid supplemental payment programs, specifically the Nevada State Directed Payment program.
Guidance, Outlook, and Risks
- Capital Expenditures: UHS expects to spend between $850 million and $1 billion on capital expenditures for the full year 2025. Approximately $239 million was spent in Q1, with $611 million to $761 million expected for the remainder of the year.
- Share Repurchases: The company repurchased approximately 1.0 million shares for $180.6 million in Q1 2025. As of March 31, 2025, approximately $643.7 million remained available under the repurchase program.
- Dividends: A quarterly dividend of $0.20 per share was declared and paid.
- Legal Contingencies:
- The Pavilion Matter: A jury verdict of $60 million compensatory and $120 million punitive damages (after remittitur) was entered against a subsidiary. UHS has reached an agreement in principle for a settlement expected to be covered by insurance and reserves, pending court approval.
- Cumberland Litigation: Multi-plaintiff lawsuits regarding inappropriate sexual contact resulted in a verdict of $60 million compensatory and $1.05 million punitive damages for three plaintiffs. Approximately 40 additional plaintiffs remain pending. UHS expects these matters to be covered by existing reserves and insurance, though exhaustion of coverage could materially impact future results.
- Regulatory Risks: Significant exposure to changes in Medicaid funding, including potential reductions in Disproportionate Share Hospital (DSH) payments starting October 1, 2025. The company also faces risks related to the "Managed Care Rule" and potential changes to provider tax programs.
Investor Verification Checklist
- Medicaid Funding Status: Verify the approval status and funding levels of state-specific Medicaid supplemental payment programs (e.g., Nevada SDP, Texas CHIRP, California programs) which significantly impact revenue recognition and receivables.
- Legal Settlement Finalization: Monitor the finalization and court approval of the settlement agreement for The Pavilion matter and the progression of the Cumberland litigation to assess potential reserve adjustments.
- Interest Rate Environment: Review the impact of the September 2024 credit agreement amendment and senior note issuances on future interest expense, noting the current lower effective rate of 4.1%.
- DSH Payment Cuts: Assess the financial impact of the scheduled Medicaid DSH payment reductions effective October 1, 2025, particularly for Texas facilities.
- Capital Allocation: Track the execution of the $850M-$1B capital expenditure plan and the utilization of the remaining $643.7M share repurchase authorization.